These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26138279)

  • 1. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
    Zhao W; Zhang D; Fakhoury M; Fahd M; Duquesne F; Storme T; Baruchel A; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3191-9. PubMed ID: 24663023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age- and gender-related differences in teicoplanin levels in paediatric patients.
    Strenger V; Hofer N; Rödl S; Hönigl M; Raggam R; Seidel MG; Dornbusch HJ; Sperl D; Lackner H; Schwinger W; Sovinz P; Benesch M; Urlesberger B; Urban C
    J Antimicrob Chemother; 2013 Oct; 68(10):2318-23. PubMed ID: 23702837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin pharmacokinetics in pediatric patients.
    Dufort G; Ventura C; Olivé T; Ortega JJ
    Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies.
    Sako KI; Nakamaru Y; Ikawa K; Maeda T; Goto S; Ishihara Y; Kato Y; Matsuda Y
    Ther Drug Monit; 2021 Aug; 43(4):519-526. PubMed ID: 34250964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.
    Ramos-Martín V; Neely MN; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; López-Herce J; Hope WW
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Pharmacodynamics of Norvancomycin in Children With Malignant Hematological Disease.
    Wang J; Li SC; Ye Q; Gao LL; Nie YM; Xu H; Wu M; Cao P; Wang Y
    J Clin Pharmacol; 2020 Sep; 60(9):1220-1230. PubMed ID: 32488878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children.
    Aarons L; Rowland M; Khan A; Taborelli G; Ferrea G; Tarantino V; Fioredda F; Rosina-Parenti R; Cavenaghi L; Borgonovi M
    Eur J Pharm Sci; 1998 Oct; 6(4):265-70. PubMed ID: 9795079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
    Lortholary O; Tod M; Rizzo N; Padoin C; Biard O; Casassus P; Guillevin L; Petitjean O
    Antimicrob Agents Chemother; 1996 May; 40(5):1242-7. PubMed ID: 8723474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.